Tomoko Oeda

Utano Hospital — Japan

Medicine · Health Sciences

29h-index2.6kcitations70works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(47), Neurological disorders and treatments(15), Dysphagia Assessment and Management(6), Botulinum Toxin and Related Neurological Disorders(5), Alzheimer's disease research and treatments(4)

Publications70 total

Astrocyte-vascular interactions are disturbed in cerebral white matter of adult-onset neuronal intranuclear inclusion disease
Journal of Neuropathology & Experimental Neurology·2026
Drug-Induced Lupus Erythematosus After 14 Years of Carbamazepine Use in a Patient With Neuromyelitis Optica Spectrum Disorder: A Case Report
American Journal of Case Reports·2025Open Access
Cortical involvement of lateral trunk flexion and verticality misperception in Parkinson’s disease
Brain Communications·2024· 3 citedOpen Access
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration
Multiple Sclerosis and Related Disorders·2022· 27 citedOpen Access
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
The Lancet Neurology·2021· 132 citedOpen Access
Early-start <i>vs</i> delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial
Expert Opinion on Pharmacotherapy·2020· 11 cited
Seeking transpaRINcy for rituximab dosing in NMOSD – Authors' reply
The Lancet Neurology·2020· 1 citedOpen Access
Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder – Authors' reply
The Lancet Neurology·2020Open Access
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2020· 348 cited
The general remarks and evidence of Levodopa carbidopa intestinal gel(LCIG)
Japanese Society of Neurology·2019
Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
Journal of Neurology Neurosurgery & Psychiatry·2018· 43 citedOpen Access
Pharmacological interventions for anxiety in Parkinson’s disease sufferers
Expert Opinion on Pharmacotherapy·2018· 14 cited
Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson’s disease
PLoS ONE·2018· 44 citedOpen Access
Low body mass index and life prognosis in Parkinson's disease
Parkinsonism & Related Disorders·2018· 29 cited
Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
Therapeutic Advances in Neurological Disorders·2018· 11 citedOpen Access
Risks and Triggers of Psychosis in Parkinson Disease
Journal of Alzheimer’s Disease & Parkinsonism·2018· 2 citedOpen Access
Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo‐controlled pilot trial
Movement Disorders·2017· 3 cited
Cerebral infarctions with hypereosinophilic syndrome: A report of two cases
Journal of the Neurological Sciences·2017
Decreased cough sensitivity and aspiration pneumonia in Parkinson disease
Journal of the Neurological Sciences·2017
Homeostasis in lipid metabolism is impaired in Parkinson's disease
Journal of the Neurological Sciences·2017· 1 cited
page 1 of 4Next →

Frequent Co-authors

Hideyuki Sawada(24), Yoshihiro Miyake(22), Keiko Tanaka(22), Wakaba Fukushima(22), Chikako Kiyohara(22), Yoshio Tsuboi(22), Nobutaka Sakae(22), Hidenao Fukuyama(22), Satoshi Sasaki(20), Masaki Nagai(19), Kenji Yamamoto(18), Atsushi Umemura(17), Nobutoshi Kawamura(17), Yoshio Hirota(16), Satoshi Tomita(16), Masayuki Kohsaka(16), Tatsuo Yamada(15), Kwiyoung Park(12), Takami Miki(10), Hiroshi Sugiyama(7)